Waqqas Afif

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif, Edward V. Loftus, William A. Faubion et al. · The American Journal of Gastroenterology · 2010 · 487 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease

Robert Battat, Uri Kopylov, Talat Bessissow et al. · Clinical Gastroenterology and Hepatology · 2017 · 234 citations

Medicine, Clinical Sciences, Immunology +16

The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients

Triana Lobatón, Talat Bessissow, Gert De Hertogh et al. · Journal of Crohn s and Colitis · 2015 · 162 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

Uri Kopylov, Waqqas Afif, A Cohen et al. · Journal of Crohn s and Colitis · 2014 · 146 citations

Medicine, Immunology, Pharmacotherapy +17

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

Waqqas Afif, Jonathan A. Leighton, Stephen B. Hanauer et al. · Inflammatory Bowel Diseases · 2009 · 129 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17